Frontline Dasatinib Treatment in a “Real-Life” Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia

Dasatinib (DAS) has been licensed for the frontline treatment in chronic myeloid leukemia (CML). However, very few data are available regarding its efficacy and toxicity in elderly patients with CML outside clinical trials. To address this issue, we set out a “real-life” cohort of 65 chronic phase C...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Neoplasia
Auteurs principaux: Latagliata, Roberto, Stagno, Fabio, Annunziata, Mario, Abruzzese, Elisabetta, Iurlo, Alessandra, Guarini, Attilio, Fava, Carmen, Gozzini, Antonella, Bonifacio, Massimiliano, Sorà, Federica, Leonetti Crescenzi, Sabrina, Bocchia, Monica, Crugnola, Monica, Castagnetti, Fausto, Capodanno, Isabella, Galimberti, Sara, Feo, Costanzo, Porrini, Raffaele, Pregno, Patrizia, Rizzo, Manuela, Antolino, Agostino, Mauro, Endri, Sgherza, Nicola, Luciano, Luigiana, Tiribelli, Mario, Russo Rossi, Antonella, Trawinska, Malgorzata, Vigneri, Paolo, Breccia, Massimo, Rosti, Gianantonio, Alimena, Giuliana
Format: Artigo
Langue:Inglês
Publié: Neoplasia Press 2016
Sujets:
Original article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5031865/
https://ncbi.nlm.nih.gov/pubmed/27659013
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.neo.2016.07.005
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires